Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement
Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ. Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal Of Nuclear Cardiology 2022, 29: 2748-2760. PMID: 35838892, PMCID: PMC9285188, DOI: 10.1007/s12350-022-03059-5.Peer-Reviewed Original ResearchAmyloidosisCardiomyopathiesDiphosphatesDiphosphonatesHumansPrealbuminRadiopharmaceuticalsTechnetium Tc 99m Pyrophosphate